Novartis said that it is exploring an additional direct-to-employer model to increase access and affordability for cash-paying patients in the United States.
Amneal submits a BLA for a new Xolair biosimilar, promising affordable treatment options for asthma and allergies, enhancing ...
If approved, Awiqli would become the first once-weekly basal insulin available in the United States for adults with Type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback